Thalidomide and its analogues can inhibit the synthesis of TNF-α by activated monocytes and have demonstrated efficacy in autoimmune diseases such as RA (85), SLE (86), and systemic sclerosis, although the precise mechanisms were previously unknown (87). Here, TNF is linked to autoimmune disease.